Agenus Inc. (NASDAQ:AGEN - Get Free Report) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $3.44 and traded as high as $6.57. Agenus shares last traded at $6.09, with a volume of 750,753 shares.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on AGEN shares. Robert W. Baird increased their price objective on Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research report on Wednesday, June 4th. B. Riley reiterated a "buy" rating on shares of Agenus in a report on Monday, April 21st. HC Wainwright upgraded Agenus from a "neutral" rating to a "buy" rating and set a $25.00 price objective for the company in a report on Wednesday, June 4th. Finally, Wall Street Zen upgraded Agenus from a "strong sell" rating to a "hold" rating in a research note on Thursday, May 22nd.
Check Out Our Latest Report on Agenus
Agenus Price Performance
The company has a market capitalization of $166.30 million, a PE ratio of -0.70 and a beta of 1.51. The company has a 50-day moving average of $5.01 and a two-hundred day moving average of $3.51.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.58. The business had revenue of $24.07 million during the quarter, compared to analysts' expectations of $26.38 million. As a group, research analysts anticipate that Agenus Inc. will post -12.55 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Corton Capital Inc. purchased a new stake in shares of Agenus during the 4th quarter valued at $36,000. Apollon Wealth Management LLC boosted its holdings in Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after buying an additional 5,000 shares during the last quarter. Virtu Financial LLC purchased a new position in Agenus in the 4th quarter worth approximately $51,000. Acadian Asset Management LLC purchased a new stake in shares of Agenus during the 1st quarter valued at approximately $58,000. Finally, Bank of Montreal Can acquired a new stake in Agenus in the 4th quarter valued at approximately $69,000. Institutional investors own 61.46% of the company's stock.
Agenus Company Profile
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Articles
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
